First Hawaiian Bank’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-12,243
| Closed | -$1.67M | – | 517 |
|
|
2024
Q4 | $1.67M | Buy |
12,243
+2,150
| +21% | +$293K | 0.05% | 272 |
|
|
2024
Q3 | $1.16M | Buy |
10,093
+4,610
| +84% | +$531K | 0.04% | 382 |
|
|
2024
Q2 | $755K | Buy |
5,483
+320
| +6% | +$44.1K | 0.03% | 442 |
|
|
2024
Q1 | $712K | Sell |
5,163
-105
| -2% | -$14.5K | 0.02% | 503 |
|
|
2023
Q4 | $694K | Buy |
5,268
+1,685
| +47% | +$222K | 0.02% | 495 |
|
|
2023
Q3 | $403K | Buy |
3,583
+900
| +34% | +$101K | 0.01% | 634 |
|
|
2023
Q2 | $253K | Sell |
2,683
-8,750
| -77% | -$825K | 0.01% | 756 |
|
|
2023
Q1 | $1.16M | Sell |
11,433
-3,195
| -22% | -$323K | 0.04% | 332 |
|
|
2022
Q4 | $1.75M | Sell |
14,628
-650
| -4% | -$77.7K | 0.06% | 235 |
|
|
2022
Q3 | $1.62M | Buy |
15,278
+15
| +0.1% | +$1.59K | 0.06% | 222 |
|
|
2022
Q2 | $1.49M | Buy |
15,263
+6,435
| +73% | +$627K | 0.05% | 253 |
|
|
2022
Q1 | $827K | Buy |
8,828
+35
| +0.4% | +$3.28K | 0.03% | 442 |
|
|
2021
Q4 | $749K | Buy |
+8,793
| New | +$749K | 0.02% | 477 |
|
|
2021
Q1 | – | Sell |
-3,078
| Closed | -$295K | – | 862 |
|
|
2020
Q4 | $295K | Sell |
3,078
-145
| -4% | -$13.9K | 0.01% | 666 |
|
|
2020
Q3 | $310K | Buy |
+3,223
| New | +$310K | 0.02% | 587 |
|
|
2019
Q2 | – | Sell |
-127
| Closed | -$11K | – | 1242 |
|
|
2019
Q1 | $11K | Sell |
127
-241
| -65% | -$20.9K | ﹤0.01% | 1374 |
|
|
2018
Q4 | $26K | Buy |
368
+58
| +19% | +$4.1K | ﹤0.01% | 1244 |
|
|
2018
Q3 | $38K | Buy |
+310
| New | +$38K | ﹤0.01% | 1228 |
|